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Abstract: 
Background: Polymerase chain reaction (PCR) nasal swabs are used for methicillin resistant 
Staphylococcus aureus (MRSA) colonization screening. Previous institutional data demonstrated 
that screening protocols based on admission unit resulted in a high yield of negative results and 
higher costs. The objective of this study was to determine risk factors associated with MRSA 
colonization for an improvement in targeted screening. 
 
Methods: This is a retrospective study of potential risk factors included for analysis based on 
availability within the medical record. Patients were included if admitted between 2016 and 2018 
with a MRSA PCR screen obtained within 48 hours. Multivariate logistic regression was used to 
identify characteristics associated with MRSA colonization. 
 
Results: Preliminary results using logistic regression (c-statistic = 0.81) included 9,269 MRSA 
negative and 2,427 MRSA positive encounters. Admission from a skilled facility (odds-ratio: 
2.74), acute (6.92) or history of MRSA infection (2.63), homelessness (1.81), skin and 
subcutaneous tissue infection (1.71), chronic obstructive pulmonary disease (1.36), venous 
thromboembolism (1.41), and skin ulcer (1.44), were positively associated with MRSA 
colonization. The number of hospitalizations in the past 90 days and the number of 
hospitalizations in the past 91 to 365 days were not adequately generated in the MRSA negative 
group for analysis. 
 
Conclusions: Due to errors in data collection the results of this study are invalid. Further 
research is needed to determine the true effect of recent hospitalization on MRSA colonization 






















Methicillin-resistant Staphylococcus Aureus (MRSA)  was identified as the causative pathogen 
in over half of nosocomial infections in a multicenter prevalence study, and infections caused by 
MRSA can be serious.1 In 2011 it was estimated that 4% of patients develop at least one 
nosocomial infection during hospitalization. The direct medical costs from hospital-acquired 
infections ranged from roughly $20,000 to $26,000 per patient in 2007.2 This cost is based on 
hospital expenditures to provide medications, nutrition, procedures, supplies, and more. 
Reimbursement rates for hospital-acquired infections through Medicare vary depending on the 
health system’s performance. Hospitals can face penalties in the form of payment reductions if 
they have higher than average rates of hospital-acquired infections.3 The prevalence of MRSA, 
the high cost of treating nosocomial infections, and risk of financial penalties create the potential 
for an overall monetary loss for the hospital.  
 
In 1995 the Center for Disease Control (CDC)initiated “The Active Bacterial Core” surveillance 
system to track infectious diseases documented by the health departments of individual states.4  
The  CDC uses this data to assess vaccine efficacy and disease trends, and the program was 
expanded in 2004 to include MRSA surveillance. Tracking of nosocomial infections led to 
reduction initiatives, including implementing screening policies and requirements for personal 
protective equipment (e.g. gloves, gowns, masks). As a result, in the subsequent six years, the 
CDC was able to report a 54.2% decline in the incidence of hospital-onset infections, and a 5% 
decline in community associated MRSA infections.5 
 
Mission Hospital is an 812-bed tertiary care hospital located in a metropolitan area of Asheville, 
North Carolina. It serves as the main hub of Mission Health System, a six-hospital network 
located in Western North Carolina. In 2006, Mission Hospital piloted an active MRSA 
surveillance study due to increasing rates of nosocomial MRSA. Patients admitted to the 
intensive care unit (ICU) were screened for nasal MRSA colonization obtained through 
polymerase chain reaction (PCR) testing of nasal swabs.6 When the PCR result was positive, 
contact precautions were implemented, requiring gowns and gloves to be worn by all health care 
workers who entered the patient’s room and prohibited nonessential healthcare providers  from 
entering. After that initial year-long ICU trial, nosocomial MRSA infection rates declined, and 
the PCR MRSA screen was gradually expanded to other units with high rates of nosocomial 
MRSA. The results of this initiative demonstrated a remarkable 80% decrease in nosocomial 
MRSA infections from 2006 to 2008. 6 It became hospital policy to screen all patients admitted 
to specific units of the hospital for MRSA; patient units with automatic screening were chosen 
based on nosocomial MRSA prevalence and percent MRSA PCR positive screening. 
 
Per the Centers for Medicare & Medicaid Services (CMS) reimbursement protocol for tracking 
MRSA colonization acquired during hospitalization, MRSA PCR screening was done within 48 
hours of admission to specific hospital units.7 In 2014, over ten thousand MRSA PCR screens 
were conducted at Mission Hospital during a seven-month period, costing approximately 
$217,000.  Of these tests administered, 10% were positive.  The larger number of negative PCR 
tests presents an opportunity to optimize utilization of this screening tool by better targeting 
patients with higher likelihood of a positive result.  
 
Studies have shown there is a reduced cost associated with risk-based MRSA screening 
compared to universal screening that is not associated with an increase in nosocomial MRSA 
infections.8 The most commonly identified risk factors were nursing home residence, previous 
hospitalization, skin or bone infection, diabetes, heart disease, lung disease, kidney disease, and 
immunosuppression.9-12 However, results of the analyses and definitions of certain comorbidities 
were widely varied, and the lack of agreement in published literature  make it difficult to 
extrapolate data to other patient populations. One study published in 2011 validated a number of 
models to predict MRSA colonized patients; however, it was focused on identifying patients not 
previously known to be colonized. As such, patients with a history of MRSA colonization were 
omitted, and data that would only be available after a day of admission were included in the 
analysis.9  
 
The present study utilized a standardized approach to diagnostic nomenclature through the 
International Classification of Diseases, Tenth Revision, Clinical Modification (ICD10-CM) 
coding system.  ICD10 codes are recorded in a patient’s hospital encounter and can be accessed 
through the electronic medical record (EMR). The primary objective was to determine risk 
factors available on admission that were positively associated with a subsequently positive 
MRSA PCR nasal swab. The secondary objective was to utilize significant risk factors identified 
as a basis for building a risk algorithm into the EMR to automatically calculate risk for MRSA 




Data were extracted retrospectively from Mission Hospital’s EMR program using data analytics 
software. Inpatient and observational patient encounters were included if: (1) admission date was 
between January 1st, 2016 and January 1st, 2018; (2) patient was at least 18 years of age on 
admission, and (3) if the MRSA PCR screen resulted as positive or negative within 48 hours 
from presentation. Only the most recent encounter was included for patients who presented 
multiple times during this time frame. Per Mission Hospital’s MRSA surveillance protocols, 
MRSA PCR screening data was available for all patients admitted to ten hospital units (3 ICUs 
and 7 general medical units) and patients having cardiothoracic or orthopedic surgery.  The 
Mission Hospital Institutional Review Board and Research Institute approved the study protocol. 
 
Variables 
Thirty-four risk factors for MRSA were identified for analysis from existing published literature 
and through consensus agreement with practitioners and clinical pharmacists.  Risk factors were 
categorically separated into patient demographics, previous hospitalization factors, and 
comorbidities (Table 1).  Comorbidities were included as ICD10 diagnostic codes.  ICD10 codes 
were grouped into 23 broader disease states, then were separated into chronic and acute 
conditions.   
 




- Body Mass Index 
- Admission from SNF 
- Admission from law enforcement 
- Homelessness 
Previous Hospitalization Factors 
- In the past 90 days: 
- Number of positive MRSA PCRs 
- ICU exposure 
- Number of hospitalizations in 90 days 
- Number of hospitalizations in 91-365 days 
 
- Vancomycin exposure 
- Non-vancomycin antibiotic exposure 
 
Comorbidities 
- Acute:  
- MRSA Infection 
- Skin and subcutaneous tissue 
infection  
- Acute venous thromboembolism 
- Acute congestive heart failure 
- Transient ischemic attack or stroke 
- Renal failure 
- Clostridium difficile infection 
- Chronic: 
- History of MRSA infection 
- Chronic obstructive pulmonary 
disease 
- Chronic venous thromboembolism 
- Chronic skin ulcer 
- Chronic congestive heart failure 
- Hemodialysis 
- Cystic fibrosis 
- End stage renal disease 
- Chronic kidney disease  
- Diabetes mellitus 
- Substance related disorders 
- Human immunodeficiency virus 
- Immunity disorders  
- Other chronic pulmonary diseases 
ICU intensive care unit; SNF skilled nursing facility.  
All patient demographic and previous hospitalization risk factors were able to be electronically 
abstracted from the EMR from previous visits within Mission Health System.  All chronic 
comorbid conditions were included regardless of present on admission designation. Acute 
comorbid conditions were those designated as present on admission for inclusion in the analysis 
(i.e. no new diagnoses made during the index hospitalization were considered for this study).    
 
Statistical Methods 
A logistic regression was performed to predict the probability of screening positive for MRSA. 
Independent variables were the risk factors previously described. A two-way interaction between 
HIV and antibiotic exposure in the past 90 days (both vancomycin and other) as well as cancer 
and antibiotic exposure in the past 90 days was also included. These interacting variables were 
found to be significant in two journal articles, no other two-way interactions were analyzed.10,11 
Continuous variables included: body mass index (BMI), age, number of hospital visits in the past 
90 days, number of hospital visits in the past 91 to 365 days, and number of positive MRSA PCR 
screens in the past 90 days. To allow for nonlinear relationships between numeric variables and 
the outcome, the five numeric variables were modeled with restricted cubic splines. Age, BMI, 
number of hospital visits in the past 90 days, and number of hospital visits from 91 to 365 days 
ago received five knots, while number of positive PCR screens in the past 90 days was modeled 
with three knots due to its limited data range.  
 
To determine the predictive capability of this model, bootstrap resampling validation with 100 
samples was conducted. Area under the curve (equivalent to the c-statistic) was then calculated 
to determine the accuracy of the model.  An AUC of 1.0 indicates the model will predict the 
outcome with 100% accuracy.  A p-value of <0.05 was considered statistically significant. All 
analyses were performed using the statistical software R version 3.5.0. 
 
Results: 
The preliminary results of the multivariate analysis of thirty-four risk factors are reported in 
Table 2. The c-statistic of the multivariate regression model is 0.8096. Thirteen risk factors were 
found to be statistically significant with at least one factor from each category; patient 
demographics, previous hospitalization, acute comorbidities, and chronic comorbidities. The 
strongest linear risk factors include: acute MRSA infection present on admission (OR: 6.71, CI: 
3.62-13.2), admission from a skilled nursing facility (OR: 2.71, CI: 2.12-3.53), history of MRSA 
infection (OR: 2.63, CI: 1.78-3.89), acute skin and soft tissue infection present on admission 
(OR: 1.71 , CI: 1.33-2.20), and chronic obstructive pulmonary disease (OR: 1.36, CI: 1.18-1.58). 
Homelessness (OR: 1.81, CI: 1.04-3.16), chronic VTE (OR: 1.41, CI: 1.10-1.82) and chronic 
skin ulcers (OR: 1.44, CI:1.08-1.91) were also found to have a significant positive correlation 
with MRSA colonization.   
 
Non-vancomycin antibiotic exposure (OR: 0.33, CI: 0.25-0.44) and number of hospital visits in 
the past 91 to 365 days (OR: 0.59, CI: 0.52-0.67) were found to have a negative correlation with 
MRSA colonization. The two-way interacting variables of cancer with antibiotics (p = 0.4581) 
and HIV with antibiotics (p = 0.7542) were both found to be non-significant. 
 
Table 2. Multivariate analysis results of 34 risk factors. 
Risk Factors 
Multivariate Analysis 
OR 95% CI P value 
Patient Demographics    
Admit from skilled nursing facility 2.74 2.12-3.53 <0.0001 
Age* 1.19 1.00-1.41 0.0002 
BMI* 1.01 0.87-1.17 0.0186 
Homelessness 1.81 1.04-3.16 0.0362 
Admit from law enforcement 0.60 0.13-2.79 0.5164 
Sex  0.99 0.88-1.10 0.7937 
    
Hospitalization Factors    
Number of hospitalizations in the past 90 
days 
25.8 21.0-31.5 <0.0001 
Number of hospitalizations in the past 91 
to 365 days 
0.59 0.52-0.67 <0.0001 
Non-Vancomycin antibiotic exposure in 
the past 90 days 
0.33 0.25-0.44 <0.0001 
Vancomycin exposure in the past 90 days 0.70 0.49-1.00 0.2145 
ICU exposure in the past 90 days 0.78 0.48-1.24 0.2882 
Positive MRSA PCR screens in the past 
90 days 
1.39 0.18-10.6 0.8083 
    
Acute Comorbid Conditions    
MRSA Infection 6.92 3.62-13.2 <0.0001 
Skin and subcutaneous tissue infection 1.71 1.33-2.20 <0.0001 
Acute venous thromboembolism 0.76 0.47-1.23 0.2632 
Acute congestive heart failure† 1.34 0.98-1.84 0.0675 
Transient ischemic attack or stroke 1.19 0.85-1.66 0.3146 
Renal Failure 1.08 0.91-1.29 0.3763 
Clostridium difficile infection 1.20 0.69-2.09 0.5235 
    
Chronic Comorbid Conditions    
History of MRSA infection 2.63 1.78-3.89 <0.0001 
Chronic obstructive pulmonary disease 1.36 1.18-1.58 <0.0001 
Chronic venous thromboembolism 1.41 1.10-1.82 0.0071 
Chronic skin ulcer 1.44 1.08-1.91 0.0122 
Cancer 0.82        0.68-1.00   0.0529 
Substance related disorders 1.19 0.91-1.56 0.1985 
Human immunodeficiency virus 2.05 0.97-4.37 0.3170 
Immunity disorders 0.68 0.28-1.63 0.3838 
Other chronic pulmonary diseases 0.72 0.34-1.55 0.4048 
Chronic congestive heart failure 1.09 0.89-1.33 0.4068 
Hemodialysis 0.74 0.36-1.53 0.4188 
Cystic fibrosis 0.47 0.03-7.35 0.5875 
End stage renal disease 1.15 0.58-2.29 0.6929 
Chronic kidney disease 0.99 0.82-1.19 0.8744 
Diabetes mellitus 1.00 0.87-1.14 0.9706 
    
CI confidence interval, OR odds ratio. 
*The Age and BMI confidence intervals appear to cross 1, but the p value is still <0.05 and these 
risk factors are statistically significant. This occurs due to the upper and lower limit of the 
confidence interval defaulting to the 75th and 25th percentile respectively. The significant ranges 
fall out side of the confidence interval, as illustrated in Figure 1. 
†Acute congestive heart failure includes ICD10 codes specified as “acute on chronic”. 
 
Four significant factors were collected as continuous variables and had a significant non-linear 
relationship with MRSA colonization shown in Figure 1. Data was incomplete for the number of 
hospitalizations in the past 90 days and the number of hospitalizations in the past 91 to 365 days 
due to technical difficulties. Blank entries were incorrectly interpreted as zero. Based on skewed 
data, the number of hospital visits in the past 90 days (OR: 25.8 CI: 21.0-31.5) was initially 
determined to be significant. The risk for colonization peaks around 2 hospital visits, then trends 
down before increasing again after 5 or more visits. Age and BMI had similar shaped curves and 
increased risk associated with being on the lower or higher end of either range. Number of 
hospital visits in the past 91 to 365 days showed more encounters associated with a decreasing 
risk of MRSA colonization. 
 







Age (years) Number of Hospital visits past 90 days 
Number of Hospital visits 91 to 365 days BMI (kg/m2) 
Initial results indicated  that certain patient characteristics available on admission were positively 
associated with MRSA colonization including: admission from a SNF, age, BMI, homelessness, 
hospital visits in the past 90 days, acute MRSA infection, acute SSTI, a history of MRSA 
infection, COPD, chronic VTE, and chronic skin ulcer. However, multivariate analysis studies 
simultaneously determine independent significance and correlation between each variable. 




These results are invalid and are not an accurate representation of the risk factors that are 
positively associated with MRSA colonization. Upon post-analysis review, it was determined 
that data was not generated for a significant portion of the MRSA negative group. Incomplete 
data was converted to a zero value which was defined as having no recent hospitalizations in the 
analysis. This would account for our initial findings that suggested multiple admissions to the 
hospital within a three-month window profoundly increases an individual’s risk for being 
colonized with MRSA at their next admission. This error affects the validity of the other data 
points as well.  
 
We expected our results would not mirror other published studies for risk factors found to be 
correlated with MRSA colonization. Most MRSA colonization prediction models analyze a 
similar set of data points consisting of common co-morbidities, previous hospitalization, use of 
antibiotics, and immunosuppressing conditions.8-12 However, the results often are varied. This is 
probably due to different prevalence of MRSA colonization and different comorbidities typical 
of the patient population. Available literature also evaluates different hospitalization and time 
measures including: hospitalization in the past 12 months, hospitalization in the past 18 months, 
and hospitalization lasting greater than 7 days in the past year.9-12 There is a still undefined 
relationship between MRSA colonization risk and time from most recent previous hospitalization 
that needs to be evaluated further. This highlights the utility of developing a site-specific 
predictive model to determine the MRSA colonization risk factors unique to an institution.  
 
Our next analysis will include other pertinent antibiotic classes and route of administration 
including: enterally, parenterally, and topically. Other studies have separated antibiotics into 
MRSA active and not MRSA active.7 The results showed MRSA active antibiotics were not 
significant, consistent with our findings that vancomycin was not significant. Additionally, their 
results showed cephalosporins were a negative predictor while other antibiotics were a positive 
predictor. We expected that since vancomycin is an antibiotic that is used to treat MRSA 
infections, recent exposure may decrease risk of colonization, while exposure to other antibiotics 
may select for the resistant bacteria. Further analysis into classes of antibiotics and route of 
administration of antibiotics is needed to determine the true effect on colonization risk. 
 
A subsequent analysis will be completed to address the skewed data points. The next sample will 
not have reductions in the MRSA negative group and will be expanded to include patients 
admitted from October 1st, 2015 to October 1st, 2019. These dates were chosen based on the 
transition from ICD9 to ICD10 and the date that a new emergency department tower was 
operationalized at Mission Hospital. This will increase the sample size and improve the 
generalizability of the model. Additionally, comorbidities will be defined using Clinical 
Classification Systems, a database maintained by the federal government to group ICD10 codes 
into larger categories. This approach, as opposed to using custom groupers, will allow us to more 
easily re-assess the predictive model over time. To utilize this model at admission, ICD10 codes 
will only be included if they were inputted during a previous encounter. We believe these 
changes will address the limitations encountered during this study. 
 
Limitations: 
Our data are limited by current screening protocols and are not a true reflection of the greater 
hospital population. This limits generalizability of the model and may affect the accuracy if 
Mission Hospital admission population varies considerably from our sample.  Additionally, our 
proportion of MRSA positive patients to MRSA negative patients is much larger than expected 
in the general population due to the reduction in sample size of the negative population.  This 
approach allowed us to capture significantly more MRSA positive subjects compared to other 
studies and provided a more manageable total sample size so we could evaluate a larger number 
of risk factors. The data available for the MRSA negative group was further reduced for the 
number of hospitalizations risk factor. This was an unintentional error. 
 
Chronic disease states and homelessness variables were included as ICD10 codes that were 
inputted at any point during hospitalization. This poses an obvious barrier to using this model if 
these data points are not available on admission. However, the distinction was allowed because 
chronic disease states and homelessness are long standing components of a patient’s health 
history and will influence colonization even if a patient is newly diagnosed during the course of 
the hospitalization. If they are previously diagnosed, this information will likely be available in 
the patient’s EMR or will be documented on admission by a provider as a part of their past 
medical history.  
 
Conclusions: 
The results of this study are not an accurate analysis of risk factors positively associated with 
MRSA colonization for this sample. Future studies will reassess the data points in a complete 
sample. Results from that study may be used to redefine the MRSA screening protocols as 
Mission Hospital. However, further evaluation of utility measures and the cost effectiveness of 
the predictive model need to be done prior to implementation.  
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